Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming more common, affecting 30% of the US adult population.1 With recent advancements in noninvasive laboratory testing, primary care physicians are in an ideal position to proactively identify patients at risk for progressive fibrosis and help prevent the development of cirrhosis and comorbidities.2
In this article:
Clinical challenge | Why it matters | Ordering recommendations | Interpreting test results | Next steps | Supporting resources
MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is becoming increasingly common among US adults.
This condition affects approximately 30% of US adults and is even more prevalent in individuals with type 2 diabetes, with up to 65% of individuals. These patients have a higher risk of developing metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis.1,3
Despite the prevalence of MASLD within the patient population, the disease remains underdiagnosed in routine clinical practice.2 Primary care liver evaluations have historically relied upon serum alanine aminotransferase (ALT) levels. However, clinical studies show that more than 79% of patients identified as high risk for advanced liver fibrosis present with normal ALT levels.4 Now, multiple societies support increased screening using noninvasive liver tests in individuals at risk for MASLD.1-3
Multiple societies, including the American Association of Clinical Endocrinology (AACE), American Association of the Study of Liver Disease (AASLD), and the Clinical Care Pathway for the Risk Stratification and Management of Patients with MASLD from the American Gastroenterological Association (AGA), recommend expanded screening for at-risk groups, including 1-3
Guidelines now recommend a noninvasive testing (NIT) strategy using the FIB-4 Index as a first-line assessment followed by secondary testing like the ELF Score to evaluate advanced liver fibrosis.3
The Fibrosis-4 (FIB-4) index is a simple, noninvasive approach that uses laboratory measures like aspartate aminotransferase (AST), ALT, and platelet count combined with patient age to help identify if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Clinical guidelines recommend FIB-4 index as the primary screening tool for individuals with type 2 diabetes and suspected MASLD. Patients identified as low risk can be reassessed every 2-3 years to monitor disease progression.3
In patients with indeterminate or high risk following a primary assessment such as FIB-4 index, a secondary assessment like the enhanced liver fibrosis (ELF) score is recommended to further stratify risk. The ELF score helps predict progression to cirrhosis and liver-related events (LREs).3
The ELF score is derived from an algorithm that combines the measurements of 3 extracellular matrix components involved in the development of liver fibrosis. Together, these assays measure qualitative and quantitative changes in the extracellular matrix (ECM).
Because the progression of MASLD can be clinically silent, patients may not know they have it. Biomarkers and noninvasive tests like the FIB-4 index and ELF score can help identify patients at risk of progressing to MASH and liver fibrosis.
Components include albumin (223), albumin/globulin ratio (calculated), alkaline phosphatase (234), ALT (823), AST (822), BUN/creatinine ratio (296), calcium (303), carbon dioxide (310), chloride (330), creatinine with eGFR (375), globulin (calculated), glucose (483), potassium (733), sodium (836), total bilirubin (287), and total protein (754), urea nitrogen (294), platelet count (723), and FIB-4 index (calculated).
Note: Each of the component tests may also be ordered individually.
Components include albumin (223), albumin/globulin ratio (calculated), alkaline phosphatase (234), ALT (823), AST (822), BUN/creatinine ratio (296), calcium (303), carbon dioxide (310), chloride (330), creatinine with eGFR (375), globulin (calculated), glucose (483), potassium (733), sodium (836), total bilirubin (287), and total protein (754), urea nitrogen (294), platelet count (723), and FIB-4 index (calculated), Enhanced Liver Fibrosis.
Note: Each of the component tests may also be ordered individually.
Components include albumin (223), albumin/globulin ratio (calculated), alkaline phosphatase (234), ALT (823), AST (822), BUN/creatinine ratio (296), calcium (303), carbon dioxide (310), chloride (330), creatinine with eGFR (375), globulin (calculated), glucose (483), potassium (733), sodium (836), total bilirubin (287), and total protein (754), urea nitrogen (294), platelet count (723).
Note: Each of the component tests may also be ordered individually.
* CPT code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
For all testing indications, an elevated FIB-4 index may indicate an increased likelihood of advanced fibrosis, whereas a low FIB-4 index may indicate a lower likelihood of advanced fibrosis. Consider additional assessment for patients with an indeterminant result.
| Interpretation information for the FIB-4 index, by testing indication5 | |||
|---|---|---|---|
| Indication for testing | Compatible with the absence of advanced fibrosis* | Compatible with the presence of advanced fibrosis* | Indeterminate result |
| MASLD (formerly known as NAFLD, or nonalcoholic fatty liver disease) | <1.30 | >2.67 | 1.30-2.67 |
| * Advanced fibrosis is defined as stage F3 (bridging fibrosis) or F4 (cirrhosis). | |||
The ELF score indicates the risk of disease progression to cirrhosis or liver-related events based on established thresholds.
| Interpretation of ELF test results6 | |
|---|---|
| ELF score | Risk of disease progression* |
| <9.80 | Lower |
| ≥9.80 and <11.30 | Mid** |
| ≥11.30 | Higher |
| * Disease progression includes development of cirrhosis or liver-related events. | |
| ** Mid risk is similar to the pre-test risk (likelihood of disease progression in the intended use population without considering the ELF score). | |
The paradigm for managing metabolic liver disease in primary care is undergoing a significant transformation. Implementing noninvasive biomarkers serves as an essential gateway for primary care clinicians to risk-stratify patients efficiently and identify those who may benefit from specialist referral and emerging therapeutic options.
Furthermore, the clinical management landscape for MASH is rapidly advancing. In addition to resmetirom, the first-ever FDA-approved treatment targeting MASH fibrosis, recent practice guidance updates from the American Association for the Study of Liver Diseases (AASLD) recommend clinicians consider semaglutide therapy for managing MASH.7 This indication is indicated for patients with moderate-to-advanced fibrosis (consistent with stages F2-F3), identified using noninvasive tests (NITs) such as ELF Score (9.2-10.5).7-8
Accurate noninvasive risk stratification helps ensure that patients are staged early enough to receive comprehensive multidisciplinary care, specialist intervention, and emerging disease-modifying pathways before progression to decompensated cirrhosis occurs.
Reach out to your Quest representative for additional information on test ordering, reflex options, and cardiometabolic laboratory services.
The CPT ® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
References
1. Kanwal F, Bril F, Wong V, et al. Clinical care pathway for the risk stratification and management of patients with metabolic dysfunction–associated steatotic liver disease. Gastroenterology. 2026;171(1):164-183. doi:10.1053/j.gastro.2026.01.047
2. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
4. Xiao TG, Witek L, Bundy RA, et al. Identifying and linking patients at risk for MASLD with advanced fibrosis to care in primary care. J Gen Intern Med. 2025;40(3):629-636. doi:10.1007/s11606-024-08955-9
5. Quest Diagnostics. Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel. Accessed September 16, 2026. https://testdirectory.questdiagnostics.com/test/test-guides/TS_FIB4/liver-fibrosis-fibrosis-4-fib-4-index-panel
6. Quest Diagnostics. Enhanced Liver Fibrosis (ELF) Score. Accessed September 16, 2026. https://testdirectory.questdiagnostics.com/test/test-guides/TS_ELF/enhanced-liver-fibrosis-elf-score
7. Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025;83(5):1326-1340. doi:10.1097/HEP.0000000000001608
8. Shakeel L, Shaukat A, Akilimali A. Resmetirom: a breakthrough in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Health Sci Rep. 2025; Jun 18;8(6):e70920. doi: 10.1002/hsr2.70920